Clinical trial

Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell…

NCT00070096 · Memorial Sloan Kettering Cancer Center, Other · Completed

Key facts

NCT number NCT00070096
Title Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
Official title A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL
Lead sponsor Memorial Sloan Kettering Cancer Center, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
Intervention type Drug
Interventions ixabepilone
Enrollment 29
Start date Aug 1, 2003
Completion Jun 1, 2007
First posted Oct 7, 2003
Last update posted Jun 24, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies